Introduction
It was estimated that in 2005, 33% of all new cancer cases in men were prostate cancer (PC), and it is estimated that PC will be the second leading cause of death in male cancer patients. PC progresses slowly, but if malignant cells are allowed to become less differentiated, it can lead to distant metastases and death if proper treatment is not administered. Owing to this, it is recommended that men over the age of 50 years undergo annual screening for PC including prostate serum antigen (PSA) analysis and digital rectal examination. 1 If PC is allowed to progress, the malignant cells can reach an androgen-independent state 2 at which time the patient's survival time is approximately 18 months.
One treatment option for high-risk PC patients is local therapy using radiotherapy, but this treatment is most effective when the PC is organ confined. One means of maintaining an organ confined state is through the use of androgen deprivation therapy (ADT) where production of the predominant androgen, testosterone, is blocked. It has been shown that 3 months of ADT before prostatectomy in PC patients significantly increased the organ-confined disease state when compared to non-ADT-treated PC patients. 1 The goal of ADT is to reduce testosterone concentrations, and this may be accomplished by orchiectomy (surgical castration) or by the administration of estrogen, luteinizing hormone releasing hormone (LHRH) agonists, LHRH antagonists, or antiandrogens. 4 The LHRH agonist Zoladex (trade name goserelin acetate) has been shown to reduce prostate tumor size to the same degree as orchiectomy. 4 However, it is becoming more common for nonmetastatic disease, asymptomatic patients with signs of biochemical recurrence to receive ADT, and currently there are no recommended treatment limitations for this approach. 5 Long-term ADT treatment can lead to numerous side effects including hot flashes, sexual dysfunction, gynecomastia, changes in body composition, altered metabolism, osteoporosis, anemia, and negative cardiovascular system adaptations, 6 which can have deleterious effects on PC patients' quality of life. 7 Although surgical castration has been shown to impair cardiac function, 8 there have been no studies investigating the effects of ADT using chemical gonadectomy on cardiac function. Therefore, the first purpose of this study was to examine the effects of ADT on cardiac function using the LHRH agonist Zoladex.
Exercise training has been shown to improve cardiac function in both healthy 9 and diseased 10 models and has been shown to attenuate chemotherapy induced cardiovascular dysfunction. 11, 12 The positive adaptations associated with endurance exercise training are associated with improved ventricular contractile force which potentially could attenuate the cardiac dysfunction associated with ADT. As such, the second purpose of this investigation was to examine the effect of endurance training during ADT using Zoladex on cardiac function. It was hypothesized that endurance training would protect against the ADT-induced impairments in cardiac function. In addition, this study analyzed ventricular myosin heavy chain (MHC) expression to help understand one mechanism contributing to ADT-induced cardiac dysfunction.
Methods

Animals and animal care
All procedures were in accordance with the University of Northern Colorado's Institutional Animal Care and Use Committee (IACUC) guidelines. The University of Northern Colorado adheres to the policies and procedures detailed in the Guide for the Care and Use of Laboratory Animals as published by the US Department of Health and Human Services and proclaimed in the Animal Welfare Act, and follows the rules, procedures, and recommendations for the care of laboratory animals as advocated by the American Association for Accreditation of Laboratory Animal Care. Adult male SpragueDawley rats (n ¼ 70, Harlan, Indianapolis, IN, USA), 10-weeks old, weighing approximately 300 g were used in this study. Animals were housed two per cage in standard rat cages and were on a 12:12 h light:dark cycle. Animals had access to standard rat chow and distilled water ad libitum for the entire duration of this study. Upon arrival from the supplier, animals were allowed a 2-week acclimation period. Following this 2-week period, all 70 animals ran on a motorized rodent treadmill for 15 min/day at 13 m/min for 5 days to allow animals to become acclimated to treadmill running before the treatments began. The most compliant animals (n ¼ 40) of the total available animals (n ¼ 70) were selected for inclusion in the study.
Drug treatment
Compliant animals were randomly assigned to either the sedentary (n ¼ 20) or exercise group (n ¼ 20). Animals in the sedentary group were randomly assigned to receive either the LHRH agonist Zoladex (AstraZeneca, Macclesfield, Cheshire, UK) (SED þ ZOL, n ¼ 10) or a control implant (SED þ CON, n ¼ 10). Animals in the exercise group were randomly assigned to either the Zoladex treatment group (EX þ ZOL, n ¼ 10) or the control implant group (EX þ CON, n ¼ 10). Zoladex-treated animals (SED þ ZOL and EX þ ZOL) received a total of two 3.6 mg Zoladex depot formulations (goserelin acetate housed in a 5 mm long Â 1 mm wide biodegradable cylinder) implanted subcutaneously (s.c.) at the neck. One 3.6 mg depot formulation of Zoladex has been shown to be effective at depressing testosterone concentrations to castrate levels in rats for 28 days. 4 Animals received implants on days 1 and 29. Testosterone production was blocked for a total of 56 days (8 weeks). Control animals (SED þ CON and EX þ CON) received s.c. control implants at the neck on days 1 and 29. Each control implant consisted of a 5 mm long Â 1 mm wide section of biodegradable Silastic tubing (Dow Corning, Midland, MI, USA).
Training protocol
Animals in the EX þ ZOL and EX þ CON groups trained on a motorized rodent treadmill with adjustable speed and grade. Rats trained 5 days/week for 8 weeks. Animals initially ran at 13 m/min and 10% grade for 15 min. Exercise intensity and duration were gradually increased during weeks 1-6 until reaching 26 m/min and 20% grade for 60 min, and this workload was maintained for the remainder of the study (Table 1) . Animals were encouraged to run using mild electric shock at the rear of the treadmill running lanes.
Cardiac function analysis
On day 57, each animal was anesthetized with an i.p. injection of heparinized sodium pentobarbital (50 mg/kg), and when a tail pinch reflex was absent, the heart was removed and cardiac function was analyzed ex vivo. When the animal was anesthetized, the heart was quickly excised and immersed in ice-cold Krebs-Henseleit buffer (120 mM NaCl, 5.9 mM KCl, 2.5 mM CaCl 2 , 1.2 mM MgCl, 25 mM NaHCO 3 , 17 mM glucose, and 0.5 mM ethylenediamine-N, N, N, N-tetraacetic acid (EDTA), pH 7.4). Within 1 min, the aorta was cannulated and the heart was perfused with Krebs-Henseleit buffer (371C, aerated with 95% O 2 and 5% CO 2 ) using a Langendorff isolated retrograde perfused heart model. The height of the buffer column was arranged to yield a constant pressure of 80 mmHg. Each heart was allowed to equilibrate for 15 min before heart rate pacing and data collection. A microtip catheter pressure transducer (Millar Instruments, Houston, TX, USA) was inserted into the chamber of the left ventricle. The right auricle was then pierced with a stainless steel electrode, and the heart was paced at 300 b.p.m. Following 5 min of pacing, a 4 s sample of left ventricular end systolic pressure (ESP, mmHg), end diastolic pressure (EDP, mmHg), the rate of pressure development ( þ dP/dt, mmHgs), and the rate of pressure decline (ÀdP/dt, mmHgs) were recorded using a PowerLab data acquisition system (ADInstruments, Colorado Springs, CO, USA). Developed pressure was calculated by subtracting EDP from ESP. At the end of the data collection period, the heart was weighed and the ventricles were isolated, flash frozen in liquid nitrogen, and stored at À801C until MHC analysis.
MHC analysis
Ventricular homogenates were analyzed for MHC isoform distribution using SDS-PAGE modified from Talmadge and Roy. 13 Approximately 100 mg of ventricular tissue was minced in 10 volumes of 41C homogenizing buffer (250 mM sucrose, 100 mM KCl, 5 mM EDTA, and 20 mM Tris-Base, pH 6.8) and homogenized using a glass tissue grinder. Cell membranes were Endurance training and androgen deprivation DS Hydock et al further disrupted using sonication. Homogenates were centrifuged at 1000 g using a microcentrifuge for 10 min at 41C. The resultant supernatant was discarded, and the pellet was resuspended in 41C washing buffer (175 mM KCl, 0.5% Triton X-100, 2 mM EDTA, and 20 mM Tris-Base, pH 6.8) at an identical volume as the homogenization buffer. The sample was centrifuged using a microcentrifuge at 1000 g for 10 min at 41C. The resultant supernatant was discarded, and the pellet was again resuspended in washing buffer. The sample was again centrifuged at 1000 g for 10 min at 41C. The resultant supernatant was discarded, and the pellet was resuspended in final resuspension buffer (150 mM KCl and 20 mM Tris-Base, pH 7.0) at a high concentration (1/ 12 previous volume). Total protein concentration was determined using the Bradford method. A total of 0.94 mg of protein was separated using SDS-PAGE on an 8% polyacrylamide separating gel with a 4% polyacrylamide stacking gel at 100 V in a Novex Sure-Lock electrophoresis unit (Invitrogen Corporation, Carlsbad, CA, USA) until tracking dye ran off of the bottom of the gel. Gels were stained using Coomassie blue. Stained gels were scanned and protein bands were analyzed using densitometry.
Other measures
At the time of killing, blood was collected for analysis of testosterone concentration using a radioimmunoassay. Additionally, hindlimb muscles (soleus and extensor digitorum longus) were excised and weighed.
Data analysis
All results are expressed as mean7s.e.m. A two way (activity Â drug) analysis of variance (ANOVA) was used to determine group differences. If a significant F-value was observed, post hoc testing was performed using t-tests to identify individual group differences. For all procedures, significance was set at the a ¼ 0.05 level.
Results
General observations
Animal characteristics are presented in Table 2 . At the time implants were delivered, no between group body mass differences were observed (P40.05). During treadmill training, one animal from EX þ ZOL and one animal from EX þ CON were excluded from the study due to noncompliance resulting in a 90% compliance rate in both EX þ ZOL (n ¼ 9) and EX þ CON (n ¼ 9). At the time of killing, there was a significant between group body mass difference (Po0.05) with post hoc testing indicating that EX þ ZOL had a significantly lower body mass than all other groups (Po0.05). Serum testosterone concentrations at 57 days were significantly different between groups (Po0.05) with both SED þ ZOL and EX þ ZOL having lower testosterone concentrations than both SED þ CON and EX þ CON (Po0.05). Similarly, absolute and relative testicular masses were significantly lower in the Zoladex-implanted groups when compared to the control-implanted groups (Po0.05). Although absolute heart mass did not differ between the groups (P40.05), EX þ CON possessed a greater relative heart mass than SED þ CON (Po0.05), and EX þ ZOL possessed a greater relative heart mass than SED þ CON and SED þ ZOL (Po0.05). No between group differences were observed in absolute or relative solei and extensor digitorum longus masses (P40.05).
Cardiac function
All hearts were paced at 300 b.p.m., and there were no differences in coronary flow between the groups (1671, 1771, 1771, and 1670.3 ml/min in SED þ CON, SED þ ZOL, EX þ CON, and EX þ ZOL, respectively, P40.05). Left ventricular ESP was found to be significantly different between groups (Po0.05, Figure 1a) . Hearts from SED þ ZOL possessed a significantly lower left ventricular ESP than hearts from SED þ CON, EX þ CON, and EX þ ZOL (Po0.05). Treatment with Zoladex invoked a 17% decline in ESP (SED þ CON vs SED þ ZOL, 8571 vs 7272 mmHg, respectively, Po0.05), and endurance training during Zoladex treatment protected against this decrease (SED þ CON vs EX þ ZOL, 8571 vs 8772 mmHg, respectively, P40.05). Endurance training alone did not significantly affect left ventricular ESP (SED þ CON vs EX þ CON, 8571 vs 8772 mmHg, respectively, P40.05).
Left ventricular EDP was found to be significantly different between the groups (Po0.05, Figure 1b) . Post hoc analysis revealed that hearts from SED þ ZOL possessed a significantly higher left ventricular EDP 
Significantly different than SED-ZOL (Po0.05). d Significantly different than EX-CON (Po0.05). SED-CON, sedentary control (n ¼ 10). SED-ZOL, sedentary Zoladex (n ¼ 10). EX-CON, exercise control (n ¼ 9). EX-ZOL, exercise Zolandex (n ¼ 9).
Abbreviations: BM, body mass; EDL, extensor digitorum longus; T, serum testosterone.
Endurance training and androgen deprivation DS Hydock et al than hearts from SED þ CON, EX þ CON, and EX þ ZOL (Po0.05). Treatment with Zoladex resulted in a 28% increase in left ventricular EDP (SED þ CON vs SED þ ZOL, 771 vs 1071 mmHg, respectively, Po0.05). This increase, however, was attenuated when animals receiving Zoladex were endurance trained throughout the drug treatment period (SED þ CON vs EX þ ZOL, 771 vs 771 mmHg, respectively, P40.05). In addition, exercise training alone did not result in any significant changes in left ventricular EDP (SED þ CON vs EX þ CON, 771 vs 770.4 mmHg, P40.05).
There was a significant left ventricular developed pressure between group difference (Po0.05, Figure 1c) . After post hoc testing, it was determined that hearts from SED þ ZOL possessed a significantly lower developed pressure than hearts from SED þ CON, EX þ CON, and EX þ ZOL (Po0.05). Zoladex treatment resulted in a 24% reduction in developed pressure in the left ventricle (SED þ CON vs SED þ ZOL, 7871 vs 6372 mmHg, respectively, Po0.05). This Zoladex-induced cardiac dysfunction was attenuated when animals were subjected to endurance training during the 8-week drug treatment (SED þ CON vs EX þ ZOL, 7871 vs 807 2 mmHg, respectively, P40.05). Endurance training alone did not significantly affect developed pressure (SED þ CON vs EX þ CON, 7871 vs 8072 mmHg, P40.05).
There was no significant between group difference observed with rate of ventricular pressure development ( þ dP/dt, P40.05, Figure 2a) . However, the rate of ventricular pressure decline (ÀdP/dt) was found to be significantly different between groups (Po0.05, Figure 2b ) with hearts from SED þ ZOL having significantly slower rates of pressure decline than hearts from SED þ CON, EX þ CON, and EX þ ZOL (Po0.05). There was a 31% reduction in ÀdP/dt with Zoladex treatment (SED þ CON vs SED þ ZOL, À22587185 vs À1719750 mmHg/s, respectively, Po0.05) which was attenuated with endurance training (SED þ CON vs EX þ ZOL, À22587185 vs À2231782 mmHg/s P40.05). Endurance training alone did not significantly affect ÀdP/dt (SED þ CON vs EX þ CON, À22587185 vs À2059753 mmHg/s P40.05).
Myosin heavy chain
A significant between group difference in MHC isoform distribution was observed (Po0.05). Figure 3 Endurance training and androgen deprivation DS Hydock et al significantly higher percentage of the b-isoform and a significantly lower percentage of the a-isoform than ventricles from SED þ CON, EX þ CON, and EX þ ZOL (Po0.05). Zoladex treatment promoted an increased expression of the b-isoform (SED þ CON vs SED þ ZOL, 971 vs 1271%, respectively, Po0.05) and a decreased expression of the a-isoform (SED þ CON vs SED þ ZOL, 9171 vs 8871%, respectively, Po0.05). Endurance training during Zoladex treatment protected against the increased expression of the b-isoform (SED þ CON vs EX þ ZOL, 971 vs 971%, respectively, P40.05) and decreased expression of the a-isoform (SED þ CON vs EX þ ZOL, 9171 vs 9171%, respectively, P40.05).
Endurance training alone did not promote a shift in either the b-isoform (SED þ CON vs EX þ CON, 971 vs 971%, respectively, P40.05) or the a-isoform (SED þ CON vs EX þ ZOL, 9171 vs 9171%, respectively, P40.05).
Discussion
To our knowledge, the present study is the first to report that chemical gonadectomy using the LHRH agonist Zoladex promotes cardiac dysfunction in male rats. The myocardium is highly sensitive to androgens as evidenced by the fact that cardiac myocytes express androgen receptors and androgen availability results in hypertrophy of cardiac myocytes. 14 A majority of studies Endurance training and androgen deprivation DS Hydock et al investigating the effects of androgen deprivation on cardiac function have employed surgical castration (orchiectomy). Golden et al. 15 isolated cardiac myocytes from castrated rats, and it was found that castration induced a 14% reduction in peak shortening and a 16% increase in time to peak shortening when compared to cardiac myocytes isolated from intact controls. At the whole heart level, Scheuer et al. 8 analyzed ex vivo cardiac function in castrated male rats and found that androgen deprivation significantly impaired cardiac function. In the present study, treatment with Zoladex promoted a 24% reduction in left ventricular developed pressure which was associated with a 28% increase in EDP and a 17% decline in ESP. In addition, treatment with Zoladex promoted a 31% reduction in ÀdP/dt. These data suggest that chemical castration depresses cardiac function to a similar degree as surgical castration which should draw attention to the possibility of cardiac dysfunction in prostate cancer patients receiving ADT using a LHRH agonist.
Reported gonadectomy-induced cardiac dysfunction, as in the present study, may be attributed to altered androgen-androgen receptor signaling regulating the synthesis of proteins instrumental in myocyte contraction such as MHC. 16 Ventricles from orchiectomized rats have been reported to express significantly higher levels of the slow ATPase activity b-MHC isoform with concomitantly lower levels of the fast ATPase activity a-MHC isoform. 17 In fact, Rosenkratz-Weiss et al.
18
reported gender differences in a-MHC and b-MHC isoform mRNA. The mRNA for the a-MHC isoform was 736% higher in female myocardium, and mRNA for the b-MHC isoform was 469% higher in the female myocardium when compared to male myocardium. These substantial differences in mRNA levels suggest that the presence of testosterone may play an integral role in regulating the expression of cardiac MHC in male rat myocardium. In the present study, ventricles from sedentary rats receiving Zoladex expressed a significantly higher b-MHC level and a significantly lower a-MHC level than control implanted animals. It is believed that systolic function is dictated by MHC isoform distribution with an increase in b-MHC corresponding to a decrease in contractile performance. 19, 20 Korte et al. 21 reported that there was a linear relationship between the amounts of b-MHC isoform expressed and power output in isolated rat cardiac myocytes during maximal (r 2 ¼ 0.82) and submaximal (r 2 ¼ 0.82) activation. Likewise, it was shown that power output of isolated working rat hearts decreased linearly as b-MHC isoform expression increased (r 2 ¼ 0.82). Myocytes containing exclusively a-MHC isoform have been reported to possess a 217% greater peak normalized power output when compared to myocytes containing exclusively b-MHC isoform. 20 Herron and McDonald 19 showed that isolated myocytes expressing 0% a-MHC and 100% b-MHC isoforms had a 52% lower peak power output than myocytes expressing 12% a-MHC and 88% b-MHC. Similarly, Tardiff et al. 22 reported a 15% decrease in systolic function using a Langendorff preparation in transgenic mice expressing 88% a-MHC and 12% b-MHC isoforms when compared to mice expressing 100% a-MHC and 0% b-MHC isoform.
Exercise training during Zoladex treatment in the present study, however, had a cardioprotective effect. To our knowledge, there has been only one other report analyzing the effects of exercise training on the myocardium during androgen deprivation. Malhotra et al., 17 swim trained male rats for 10 weeks, 1-2 weeks after surgical castration. Gonadectomy significantly decreased the ventricular expression of the V 1 myosin isozyme (a-MHC homodimer) while swim training attenuated this alteration. The Malhotra et al. study 17 , however, did not analyze cardiac function. In the present study, endurance training protected against left ventricular dysfunction. This preservation of function was associated with an attenuated a-MHC to b-MHC shift. Thirteen weeks of endurance training has been shown to improve cardiac function and promote a significant increase in a-MHC mRNA (with no increase in b-MHC mRNA) in healthy male rats. 9 This suggests that endurance training promotes an upregulation in a-MHC mRNA which in the present study may have counteracted the Zoladexinduced upregulation in b-MHC.
The cytosol of rat myocardium expresses androgen receptors, 23 and once bound, androgens are translocated to a nuclear receptor and act as a transcription factor. 24 Androgen deprivation in the present study may have promoted a myocardial androgen receptor downregulation leading to a disruption in the normal regulation of the expression of MHC. Additionally, it is well known that thyroid hormones are instrumental in positively regulating a-MHC expression, 25 and there is evidence that orchiectomy reduces thyroid hormone concentrations. 26 Exercise, however, has been shown to enhance thyroid hormone metabolism 27 and increase myocardial thyroid hormone receptor expression. 28 This exercise-induced thyroid hormone receptor upregulation has been shown to be associated with an increased expression of a-MHC 29 and provides a possible mechanism for cardioprotection in this context.
Another possible mechanism behind the present study's chemical gonadectomy-induced cardiac dysfunction may exist. There is evidence suggesting that testosterone regulates the expression of key Ca 2 þ mobilizing proteins. Surgical gonadectomy has been shown to alter cardiac myocyte Na þ /Ca 2 þ exchanger and L-type Ca 2 þ channel mRNA 15 suggesting that androgen withdrawal may disrupt the normal expression of calcium regulating proteins which could impair cardiocyte Ca 2 þ handling abilities resulting in impaired function. Endurance training, however, has been shown to improve Ca 2 þ handling in cardiac myocytes 30 which could counteract the Ca 2 þ regulatory issues associated with hypogonadism providing yet another mechanism of exercise-induced cardioprotection. These mechanisms warrant further attention.
Another direction for future research lies in the use of older rats than used in this study. The current study utilized fairly young adult male rats to employ ADT to an organism with a rather high circulating testosterone level since testosterone concentrations have been reported to be significantly lower in middle aged rats when compared to younger rats. 31 Utilizing this model allowed for a dramatic depression in available testosterone to the myocardium, which resulted in significant cardiac dysfunction of which exercise training was cardioprotective. Future investigations should employ Endurance training and androgen deprivation DS Hydock et al similar methods in middle aged and elderly rats to explore the treatment effects in a more clinically relevant model.
In conclusion, chemical castration using the LHRH agonist Zoladex resulted in a significant impairment in cardiac function. This is congruent with reports of surgical castration inducing cardiac dysfunction; however, this is the first report of chemical castration invoking such alterations. Cardiac dysfunction was associated with significant alterations in ventricular MHC isoform distribution. Endurance training during Zoladex treatment protected against cardiac dysfunction, and this attenuated cardiac dysfunction was associated with preserved ventricular MHC isoform distribution. The findings of the current study suggest that ADTinduced cardiac dysfunction may be a factor contributing to the reduced quality of life experienced by ADT-treated PC patients, and that endurance training protects against this cardiac dysfunction possibly by preventing an a to b shift in MHC.
